SCYNEXIS, Inc. (SCYX): Price and Financial Metrics

SCYNEXIS, Inc. (SCYX): $1.45

0.16 (-9.69%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add SCYX to Watchlist
Sign Up

SCYX Price/Volume Stats

Current price $1.45 52-week high $3.87
Prev. close $1.60 52-week low $1.35
Day low $1.44 Volume 496,700
Day high $1.63 Avg. volume 208,875
50-day MA $1.66 Dividend yield N/A
200-day MA $2.18 Market Cap 54.55M

SCYX Stock Price Chart Interactive Chart >


SCYNEXIS, Inc. (SCYX) Company Bio


SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.


SCYX Latest News Stream


Event/Time News Detail
Loading, please wait...

SCYX Latest Social Stream


Loading social stream, please wait...

View Full SCYX Social Stream

Latest SCYX News From Around the Web

Below are the latest news stories about SCYNEXIS INC that investors may wish to consider to help them evaluate SCYX as an investment opportunity.

Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago

We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...

Yahoo | November 30, 2023

11 Cheapest Stocks With Biggest Upside

In this piece, we will take a look at the 11 cheapest stocks with the biggest upside. If you want to skip our introduction to stock valuation and recent market news, then take a look at 5 Cheapest Stocks With Biggest Upside. Identifying the right stocks to invest in is a science that involves evaluating […]

Yahoo | November 27, 2023

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

IND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to advanceRemediation strategies following the voluntary recall of BREXAFEMME® and the MARIO study clinical hold are being evaluatedWith cash, cash equivalents and investments of $105.2 million as of September 30, 2023, SCYNEXIS projects a cash runway of more than two years JERSEY CITY, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biote

Yahoo | November 13, 2023

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens. The analyses were presented by Mahmoud Ghannoum, Ph.D, Professor and Director Center for Medical Mycology, Case Western Reserve Universit

Yahoo | October 24, 2023

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece

JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM)

Yahoo | October 16, 2023

Read More 'SCYX' Stories Here

SCYX Price Returns

1-mo 0.00%
3-mo N/A
6-mo -33.49%
1-year -53.82%
3-year -81.34%
5-year -91.76%
YTD -34.98%
2023 42.95%
2022 -74.43%
2021 -20.26%
2020 -15.93%
2019 89.58%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!